PETMED EXPRESS INC PETS

Consumer discretionary SIC 5912 - Retail-Drug Stores and Proprietary Stores NAICS Retail Trade › Health and Personal Care Retailers › Pharmacies and Drug Retailers derived Nasdaq

PetMed Express, Inc. and subsidiaries, d/b/a PetMeds®, and as parent company of PetCareRx®, is a pioneer in pet healthcare, building a consumer-first digital platform in 1996 that transformed the way customers fulfill pet medications. Thirty years later, as a leading nationwide direct-to-consumer pet health and wellness retailer, the Company markets and sells directly to consumers through its websites (Petmeds.com and PetCareRx.com), customer contact centers, and mobile applications (iOS and Android). The Company provides access to top branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter (OTC) health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and personalized AutoShip capabilities. Our digital platform offers pet healthcare solutions for a broad range of chronic conditions, including those related to allergies, arthritis, anxiety, kidneys, hyperthyroidism, and others for cats, dogs, and horses. We also offer access to a range of non-prescription health and wellness products and Rx food, non-Rx food, and treats. PetMeds and PetCareRx receive the pet's order through our websites and mobile applications and connect to the customer's licensed veterinarian for prescription approval. Through our content website, pethealthmd.com, consumers can access educational articles for any health-related questions regarding their pets. The Company offers consumers an attractive alternative for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and valued customer service. For 30 years, PetMeds has been a trusted partner in pet health, delivering expert-backed products and pharmacy care to families.

Last close 1.22 2026-10-23
Market cap $26.4M 2026-06-30 share count
52-week range 1.15 - 4.10

Valuation FY2025 figures against the last close

P/S0.1x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield0.1%
Diluted EPS-2.74

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $179.0M$227.0M$274.1M$247.6M$272.3M$303.6M$284.1M$283.4M$273.8M$249.2M
Cost of revenue —$157.8M$189.3M$171.1M$195.3M$219.3M$202.9M$188.1M$176.0M$169.9M
Gross profit $50.2M$69.1M$84.8M$76.5M$76.9M$84.3M$81.2M$95.3M$97.8M$79.3M
SG&A $50.7M$38.6M$55.2M$41.7M$31.1M$29.7M$25.3M$24.8M$24.3M$22.8M
Total operating expenses $108.9M$70.7M$92.9M$70.5M$52.7M$53.8M$50.3M$49.1M$45.7M$41.8M
Operating income -$58.7M-$1.5M-$8.2M$6.1M$24.3M$30.5M$31.0M$46.2M$52.1M$37.5M
Pre-tax income -$57.4M-$587.0K-$6.3M$7.4M$24.2M$30.9M$33.9M$49.1M$53.8M$37.9M
Income tax $73.0K$5.7M$1.2M$2.3M$5.5M$7.0M$8.0M$11.4M$16.5M$14.1M
Net income -$57.3M-$6.3M-$7.5M$5.1M$18.7M$23.9M$25.9M$37.7M$37.3M$23.8M
EPS, basic -2.74-0.30-0.370.250.931.191.291.841.831.18
EPS, diluted -2.74-0.30-0.370.250.921.191.291.841.821.17
Shares, diluted (wtd. avg.) 20.9M20.6M20.4M20.3M20.4M20.1M20.1M20.5M20.4M20.4M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $21.4M$54.7M$55.3M$104.1M$111.1M$118.7M$103.8M$100.5M$77.9M$58.7M
Receivables $1.9M$2.3M$3.3M$1.7M$1.9M$2.6M$3.8M$2.5M$2.3M$1.8M
Inventory $13.6M$16.2M$28.6M———————
Total current assets $43.6M$78.9M$93.6M$130.4M$151.0M$161.2M$129.0M$126.4M$105.2M$81.8M
Property, plant and equipment $26.3M$28.9M$26.7M$26.2M$24.5M$25.4M$25.4M$27.1M$28.7M$30.2M
Goodwill $0$26.7M$26.7M$0——————
Other intangibles $5.5M$8.0M$11.2M$860.0K$860.0K$860.0K$860.0K$860.0K$860.0K$860.0K
Total assets $81.2M$148.7M$169.9M$167.5M$179.7M$187.5M$155.3M$154.4M$134.8M$112.8M
Accounts payable $20.9M$23.6M$37.0M$25.2M$27.5M$39.5M$19.7M$16.3M$15.3M$15.2M
Total current liabilities $52.0M$62.8M$72.2M$57.5M$56.2M$44.9M$24.3M$18.6M$18.1M$18.4M
Total liabilities $52.3M$63.6M$73.2M$57.5M$56.2M$46.2M$25.3M$19.7M$19.1M$19.4M
Retained earnings $9.3M$66.5M$71.6M$91.7M$115.3M$134.1M$126.2M$122.2M$106.3M$86.5M
Total equity $28.9M$85.1M$96.7M$110.0M$123.5M$124.9M$120.3M$134.7M$115.7M$93.4M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$28.4M$4.7M$4.3M$27.8M$18.5M$40.1M$38.8M$45.1M$37.4M$47.2M
Depreciation and amortisation $9.4M$7.0M$7.1M$3.5M$2.7M$2.4M$2.3M$2.2M$2.1M$1.4M
Stock-based compensation $1.4M-$6.6M$6.9M$6.6M$4.5M$3.3M$2.8M$3.1M$2.6M$1.9M
Capital expenditure $4.6M$5.1M$4.5M$5.3M$1.8M$2.4M$2.3M$620.0K$703.0K$10.6M
Investing cash flow -$4.6M-$5.1M-$40.7M-$10.3M-$1.8M-$2.4M-$2.3M-$620.0K-$703.0K-$10.6M
Financing cash flow -$299.0K-$181.0K-$12.4M-$24.5M-$24.4M-$22.7M-$33.3M-$21.9M-$17.5M-$15.5M
Dividends paid $21.0K$181.0K$12.4M$24.5M$24.4M$22.7M$21.8M$21.9M$17.5M$15.5M
Buybacks ————$0$0$11.5M$0——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001040130-26-000023.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -100M 0 100M 200M 300M 400M Revenue, FY2016: 249.2M Gross profit, FY2016: 79.3M Net income, FY2016: 23.8M Revenue, FY2017: 273.8M Gross profit, FY2017: 97.8M Net income, FY2017: 37.3M Revenue, FY2018: 283.4M Gross profit, FY2018: 95.3M Net income, FY2018: 37.7M Revenue, FY2019: 284.1M Gross profit, FY2019: 81.2M Net income, FY2019: 25.9M Revenue, FY2020: 303.6M Gross profit, FY2020: 84.3M Net income, FY2020: 23.9M Revenue, FY2021: 272.3M Gross profit, FY2021: 76.9M Net income, FY2021: 18.7M Revenue, FY2022: 247.6M Gross profit, FY2022: 76.5M Net income, FY2022: 5.1M Revenue, FY2023: 274.1M Gross profit, FY2023: 84.8M Net income, FY2023: -7.5M Revenue, FY2024: 227M Gross profit, FY2024: 69.1M Net income, FY2024: -6.3M Revenue, FY2025: 179M Gross profit, FY2025: 50.2M Net income, FY2025: -57.3M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $249.2M $273.8M $283.4M $284.1M $303.6M $272.3M $247.6M $274.1M $227.0M $179.0M
Gross profit $79.3M $97.8M $95.3M $81.2M $84.3M $76.9M $76.5M $84.8M $69.1M $50.2M
Net income $23.8M $37.3M $37.7M $25.9M $23.9M $18.7M $5.1M -$7.5M -$6.3M -$57.3M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Director nominations Dates and mechanics for shareholders proposing directors. Item 5.08
  • Shareholder vote Item 5.07
  • Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
  • Auditor changed Item 4.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 5912

TickerCompanyMarket capP/ERevenue growth
CVS CVS HEALTH Corp $119.55B 67.2x 7.8%
YI 111, Inc. — — -9.0%
GRDN Guardian Pharmacy Services, Inc. — — 17.9%
RDGT Ridgetech Inc. — — 10.2%